Pseudomonas Infections: all 136 studies
Page 2 of 2. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Phase I Study of Colistin Methanesulfonate SodiumCompletedNCT01449838Phase 1
- Volatile Organic Compounds in Cystic FibrosisCompletedNCT01379040
- Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis PatientsCompletedNCT01375036
- A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic TherapiesCompletedNCT01319253
- Atorvastatin in Bronchiectasis in Patients With Pseudomonas AeruginosaCompletedNCT01299194Phase 4
- Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa InfectionCompletedNCT01055847Phase 2
- Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative BacteriaCompletedNCT01041716
- Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa ColonizationCompletedNCT01035853Phase 2
- Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic FibrosisApproved for marketingNCT00989807
- Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of LifeWithdrawnNCT00977158
- Cipro Inhaler for Cystic Fibrosis Children Ages 6-12CompletedNCT00910351Phase 1
- Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"CompletedNCT00889967Phase 2
- Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas AeruginosaCompletedNCT00851435Phase 1/2
- Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic TherapyCompletedNCT00786513Phase 2
- Nebulized Ceftazidime and Amikacin in Ventilator Associated PneumoniaCompletedNCT00786305Phase 2
- Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy VolunteersCompletedNCT00778388Phase 1
- Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa ColonizationCompletedNCT00774072Phase 2
- Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent AdministrationStatus unknownNCT00752882Phase 2
- Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis AirwaysCompletedNCT00700050
- Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas AeruginosaCompletedNCT00691587Phase 1/2
- The EPIC Observational StudyCompletedNCT00676169
- Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled TobramycinCompletedNCT00634192Phase 3
- Anti-pseudomonas IgY to Prevent Infections in Cystic FibrosisCompletedNCT00633191Phase 1/2
- Lcr35 / ICU / P. AeruginosaTerminatedNCT00621803Not applicable
- Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated PneumoniaTerminatedNCT00610623Phase 2
- Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and PlaceboCompletedNCT00515229Phase 2
- Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway InfectionApproved for marketingNCT00499720
- Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common UropathogensCompletedNCT00481689Phase 4
- Scandinavian Cystic Fibrosis Azithromycin StudyCompletedNCT00411736Phase 4
- Continuous Versus Short Infusions of Ceftazidime in Cystic FibrosisTerminatedNCT00333385Phase 4
- Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)CompletedNCT00235690Not applicable
- Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)CompletedNCT00153634Not applicable
- The Role of Bacteria and Genetic Variations in Cystic FibrosisCompletedNCT00043225
- Role of Toxins in Lung Infections Caused by Pseudomonas AeruginosaCompletedNCT00027183
- Tissue Collection From People With Cystic FibrosisCompletedNCT00015756
- Benefits and Risks of Newborn Screening for Cystic FibrosisCompletedNCT00014950Not applicable